330 related articles for article (PubMed ID: 21617168)
1. The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivo.
Carter RI; Mumford RA; Treonze KM; Finke PE; Davies P; Si Q; Humes JL; Dirksen A; Piitulainen E; Ahmad A; Stockley RA
Thorax; 2011 Aug; 66(8):686-91. PubMed ID: 21617168
[TBL] [Abstract][Full Text] [Related]
2. Aα-Val360: a marker of neutrophil elastase and COPD disease activity.
Carter RI; Ungurs MJ; Mumford RA; Stockley RA
Eur Respir J; 2013 Jan; 41(1):31-8. PubMed ID: 22523359
[TBL] [Abstract][Full Text] [Related]
3. The Relationship of the Fibrinogen Cleavage Biomarker Aα-Val360 With Disease Severity and Activity in α1-Antitrypsin Deficiency.
Carter RI; Ungurs MJ; Pillai A; Mumford RA; Stockley RA
Chest; 2015 Aug; 148(2):382-388. PubMed ID: 25569856
[TBL] [Abstract][Full Text] [Related]
4. Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro.
Geraghty P; Rogan MP; Greene CM; Brantly ML; O'Neill SJ; Taggart CC; McElvaney NG
Thorax; 2008 Jul; 63(7):621-6. PubMed ID: 18250185
[TBL] [Abstract][Full Text] [Related]
5. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ).
Hill AT; Campbell EJ; Bayley DL; Hill SL; Stockley RA
Am J Respir Crit Care Med; 1999 Dec; 160(6):1968-75. PubMed ID: 10588615
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
[TBL] [Abstract][Full Text] [Related]
7. Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD.
Sinden NJ; Stockley RA
Eur Respir J; 2013 May; 41(5):1042-50. PubMed ID: 22936713
[TBL] [Abstract][Full Text] [Related]
8. Oxidized Alpha-1-Antitrypsin as a Potential Biomarker Associated with Onset and Severity of Chronic Obstructive Pulmonary Disease in Adult Population.
Topic A; Milovanovic V; Lazic Z; Ivosevic A; Radojkovic D
COPD; 2018 Oct; 15(5):472-478. PubMed ID: 30822244
[TBL] [Abstract][Full Text] [Related]
9. Secretory leukocyte proteinase inhibitor, alpha-1-antitrypsin deficiency and emphysema: Preliminary study, speculation and an hypothesis.
Ayad MS; Knight KR; Burdon JG; Brenton S
Respirology; 2003 Jun; 8(2):175-80. PubMed ID: 12753532
[TBL] [Abstract][Full Text] [Related]
10. A specific proteinase 3 activity footprint in α
Newby PR; Crossley D; Crisford H; Stockley JA; Mumford RA; Carter RI; Bolton CE; Hopkinson NS; Mahadeva R; Steiner MC; Wilkinson TMA; Sapey E; Stockley RA
ERJ Open Res; 2019 Jul; 5(3):. PubMed ID: 31403052
[TBL] [Abstract][Full Text] [Related]
11. The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial.
Campos MA; Geraghty P; Holt G; Mendes E; Newby PR; Ma S; Luna-Diaz LV; Turino GM; Stockley RA
Am J Respir Crit Care Med; 2019 Aug; 200(3):318-326. PubMed ID: 30965011
[No Abstract] [Full Text] [Related]
12. The role of augmentation therapy in alpha-1 antitrypsin deficiency.
Kueppers F
Curr Med Res Opin; 2011 Mar; 27(3):579-88. PubMed ID: 21226542
[TBL] [Abstract][Full Text] [Related]
13. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency.
Hubbard RC; Crystal RG
Am J Med; 1988 Jun; 84(6A):52-62. PubMed ID: 3289387
[TBL] [Abstract][Full Text] [Related]
14. Genetic and biochemical markers of obstructive lung disease in the general population.
Dahl M
Clin Respir J; 2009 Apr; 3(2):121-2. PubMed ID: 20298391
[TBL] [Abstract][Full Text] [Related]
15. Alpha-1 antitrypsin augmentation therapy.
Wewers MD; Crystal RG
COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
[TBL] [Abstract][Full Text] [Related]
16. Deletion of Serpina1a, a murine α1-antitrypsin ortholog, results in embryonic lethality.
Wang D; Wang W; Dawkins P; Paterson T; Kalsheker N; Sallenave JM; Houghton AM
Exp Lung Res; 2011 Jun; 37(5):291-300. PubMed ID: 21574874
[TBL] [Abstract][Full Text] [Related]
17. alpha-1-Antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse.
Churg A; Wang RD; Xie C; Wright JL
Am J Respir Crit Care Med; 2003 Jul; 168(2):199-207. PubMed ID: 12689849
[TBL] [Abstract][Full Text] [Related]
18. Alpha-1-antitrypsin replacement therapy: current status.
Abusriwil H; Stockley RA
Curr Opin Pulm Med; 2006 Mar; 12(2):125-31. PubMed ID: 16456382
[TBL] [Abstract][Full Text] [Related]
19. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
20. alpha1-Antitrypsin deficiency: best clinical practice.
Kalsheker NA
J Clin Pathol; 2009 Oct; 62(10):865-9. PubMed ID: 19783716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
